In this report, we retrospectively investigated the operability and effectivity of predicting response biomarker RPN2 expression using pre-treatment tissues of advanced gastric cancer patients to DCS therapy, with a particular focus on the potential of RPN2 expression as a predictor to choice patients who may benefit from docetaxel and cisplatin combination preoperative chemotherapy. The gene discussed is RPN2; the disease is gastric cancer.